Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis.

[1]  D. M. van der Heijde,et al.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) , 2013, Annals of the rheumatic diseases.

[2]  D. M. van der Heijde,et al.  Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol , 2013, Annals of the rheumatic diseases.

[3]  M. D. Di Minno,et al.  Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers , 2013, Annals of the rheumatic diseases.

[4]  M. Dougados,et al.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force , 2013, Annals of the rheumatic diseases.

[5]  D. M. van der Heijde,et al.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial , 2013, Annals of the rheumatic diseases.

[6]  D. M. van der Heijde,et al.  The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study , 2013, Annals of the rheumatic diseases.

[7]  D. Symmons,et al.  The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. , 2013, Rheumatology.

[8]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.

[9]  P. Mease,et al.  LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis , 2013 .

[10]  C. Ritchlin,et al.  OP0103 Efficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis , 2013 .

[11]  J. Greenberg,et al.  SAT0263 Biologic Therapy, Time to Low Disease Activity, and Effect of Mono Vs. Background Oral Dmard Therapy Among Psoriatic Arthritis Patients in a US Registry. , 2013 .

[12]  F. Blanco,et al.  OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial , 2013 .

[13]  A. Loft,et al.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. , 2013, Arthritis and rheumatism.

[14]  D. M. van der Heijde,et al.  Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study , 2013, Annals of the rheumatic diseases.

[15]  L. Coates,et al.  The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis , 2013, BMC Musculoskeletal Disorders.

[16]  G. Di Minno,et al.  Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis , 2013, Arthritis care & research.

[17]  G. Schett,et al.  Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. , 2012, Arthritis and rheumatism.

[18]  B. Leeb,et al.  Rituximab in psoriatic arthritis: an exploratory evaluation , 2012, Annals of the rheumatic diseases.

[19]  G. Kingsley,et al.  A randomized placebo-controlled trial of methotrexate in psoriatic arthritis , 2012, Rheumatology.

[20]  S. Srinivasan,et al.  Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study , 2011, Annals of the rheumatic diseases.

[21]  M. Dougados,et al.  European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies , 2011, Annals of the rheumatic diseases.

[22]  D. M. van der Heijde,et al.  A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis , 2011, Annals of the rheumatic diseases.

[23]  D. Gladman,et al.  LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB : 104 WEEK RESULTS FROM THE GO-REVEAL STUDY , 2012 .

[24]  J. Blacher,et al.  TNF alpha antagonist therapy and safety monitoring. , 2011, Joint, bone, spine : revue du rhumatisme.

[25]  D. Gladman,et al.  Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. , 2011, Arthritis and rheumatism.

[26]  J. Salleron,et al.  Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies. , 2011, Rheumatology.

[27]  M. Østergaard,et al.  Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. , 2011, Arthritis and rheumatism.

[28]  D. Gladman,et al.  Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study , 2010, The Journal of Rheumatology.

[29]  L. Coates,et al.  Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data , 2010, Arthritis care & research.

[30]  J. Ortonne,et al.  Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial , 2010, BMJ : British Medical Journal.

[31]  P. Goupille,et al.  Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions , 2009, Annals of the rheumatic diseases.

[32]  L. Coates,et al.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.

[33]  J. Weinberg.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2010 .

[34]  Mahboob Rahman,et al.  Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. , 2009 .

[35]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[36]  A. Gottlieb,et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2009, The Lancet.

[37]  D. Gladman,et al.  Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). , 2008, The Journal of rheumatology.

[38]  Alexander M. Fraser,et al.  Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience , 2007, Annals of the rheumatic diseases.

[39]  P. Geborek,et al.  Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register , 2007 .

[40]  F. Guillemin,et al.  Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. , 2007, Joint, bone, spine : revue du rhumatisme.

[41]  D. Gladman,et al.  Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. , 2007, Arthritis and rheumatism.

[42]  R. Scrivo,et al.  Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period , 2007, Annals of the rheumatic diseases.

[43]  D. Gladman,et al.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial , 2006, Annals of the rheumatic diseases.

[44]  Stanley B. Cohen,et al.  Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. , 2006, The Journal of rheumatology.

[45]  D. Gladman,et al.  The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year , 2006, Annals of the rheumatic diseases.

[46]  P. Claudepierre,et al.  Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. , 2005, The Journal of rheumatology.

[47]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[48]  D. Gladman,et al.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). , 2005, Arthritis and rheumatism.

[49]  J. Sharp,et al.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. , 2004, Arthritis and rheumatism.

[50]  D. Gladman,et al.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. , 2004, Arthritis and rheumatism.

[51]  P. Mease,et al.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.